Dental products company Dentsply Sirona (NASDAQ:XRAY) will be reporting earnings this Thursday afternoon. Here’s what to expect.
Dentsply Sirona beat analysts’ revenue expectations last quarter, reporting revenues of $898 million, down 4.1% year on year. It was a strong quarter for the company, with a beat of analysts’ EPS estimates and an impressive beat of analysts’ full-year EPS guidance estimates.
Is Dentsply Sirona a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Dentsply Sirona’s revenue to decline 4.9% year on year, in line with the 4.9% decrease it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Dentsply Sirona rarely misses Wall Street’s revenue estimates.
Looking at Dentsply Sirona’s peers in the healthcare equipment and supplies segment, some have already reported their Q3 results, giving us a hint as to what we can expect. Henry Schein delivered year-on-year revenue growth of 4%, meeting analysts’ expectations, and Align Technology reported revenues up 1.9%, topping estimates by 1.1%. Align Technology’s stock price was unchanged following the results.
Read our full analysis of Henry Schein’s results here and Align Technology’s results here.
There has been positive sentiment among investors in the healthcare equipment and supplies segment, with share prices up 2.8% on average over the last month. Dentsply Sirona is up 14.1% during the same time and is heading into earnings with an average analyst price target of $12.40 (compared to the current share price of $9.77).
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.